Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information has long provided a foundational framework for understanding how pharmaceutical interventions interact with human physiology. Within this broad context, public health communications have historically emphasized the benefits of medications for chronic conditions, while also acknowledging the potential for adverse effects. This balanced perspective has shaped patient awareness and clinical guidance, particularly regarding drugs with prolonged use profiles. As the domain of mass production expands, the focus shifts from generalized health education to specific occupational and environmental exposures that may arise from large-scale manufacturing processes. In the case of bisphosphonate compounds like Fosamax, the transition from therapeutic application to production environments introduces distinct considerations. Workers involved in the synthesis, handling, or packaging of such medications may encounter exposure pathways that differ from those of end-users. The pivot from a general health context to an occupational exposure concern requires examining how industrial settings could influence the risk profile, particularly for conditions such as osteonecrosis of the jaw. This transition underscores the need to evaluate not only patient outcomes but also the safety parameters for personnel engaged in mass production, where chronic low-level exposure or acute incidents may present unique challenges.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health information, we now focus specifically on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse event: osteonecrosis of the jaw (ONJ). This section examines the clinical presentation, pharmacological context, mechanistic pathways, and risk considerations regarding the relationship between Fosamax and ONJ, based solely on the provided evidence.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. According to the prescribing information, ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Fosamax Pharmacology and Reported Adverse Effects

Fosamax is a bisphosphonate that works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence in conditions like postmenopausal osteoporosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The prescribing information notes that the optimal duration of use has not been determined, and for patients at low risk for fracture, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Adverse reactions reported in clinical trials for Fosamax 70 mg once weekly and 10 mg daily were similar in safety profiles (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, ONJ is specifically listed as a warning in the labeling, indicating its recognized association with bisphosphonate therapy.

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The precise mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully detailed in the provided evidence, but research suggests that jawbone-specific responses play a role. A multiscale characterization of jawbone provides information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This implies that the unique biology of the jawbone—such as its high remodeling rate and blood supply—may make it particularly susceptible to the effects of bisphosphonates, which suppress bone turnover. The association with dental procedures and infections further supports a mechanism where impaired bone healing and local ischemia lead to necrosis.

Risk Considerations and Causation

The prescribing information includes specific warnings about ONJ. It states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known risk, its incidence in clinical trials was not significantly elevated compared to placebo, highlighting the importance of individual risk factors. For affected patients, causation considerations involve the timeline between exposure and harm. The evidence indicates that symptoms can develop rapidly (one day) or after months of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Adequacy of warnings is addressed in the labeling, which explicitly mentions ONJ and risk factors, though the evidence does not assess whether these warnings are sufficient for all patients. The prescribing information advises discontinuation if severe symptoms develop and notes that most patients improve after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence supports a causal association between Fosamax and osteonecrosis of the jaw, particularly in the presence of risk factors such as dental procedures, cancer, or concomitant medications. The timeline of onset is variable, and the risk increases with longer use. Warnings in the labeling provide guidance for clinicians and patients, but individual risk assessment remains crucial.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does Fosamax cause osteonecrosis of the jaw?

Yes, the prescribing information states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ develop?

The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.